WallStreetZenWallStreetZen

NASDAQ: APLS
Apellis Pharmaceuticals Revenue

OverviewForecastEarningsRevenue
DividendOwnership
Apellis Pharmaceuticals revenue was $1.02B for the trailing 12 months ending Sep 30, 2025, with N/A growth year over year. Quarterly revenue for the quarter (Q3 2025) ending on Sep 30, 2025 was $458.6M, up 156.9% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, APLS annual revenue was $781.4M, with 97% growth year-over-year.

APLS past revenue growth

How has APLS's revenue growth performed historically?

Company
42.11%
Industry
269.82%
Market
22.05%
APLS's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
APLS's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
APLS's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

APLS revenue history

Current Revenue
$1.0B
Current Earnings
$45.0M
Current Profit Margin
4.4%

Be the first to know when APLS announces revenue.

APLS Revenue History By Year

APLS Yearly RevenueAPLS RevenueAPLS ChangeAPLS Revenue Growth
2024-12-31$781.37M$384.78M+97.02%
2023-12-31$396.59M$321.17M+425.83%
2022-12-31$75.42M$8.86M+13.31%
2021-12-31$66.56M-$184.08M-73.44%
2020-12-31$250.65MN/AN/A
2019-12-31$0.00N/AN/A
2018-12-31$0.00N/AN/A
2017-12-31$0.00N/AN/A
2016-12-31$0.00N/AN/A
2015-12-31$0.00N/AN/A

1 of 1

Apellis Pharmaceuticals Revenue FAQ

What was APLS's revenue last quarter?

On Invalid Date, Apellis Pharmaceuticals (NASDAQ: APLS) reported Q3 2025 revenue of $458.58 million up 132.98% year over year. In the same quarter last year, Apellis Pharmaceuticals's revenue was $196.83 million.

What was Apellis Pharmaceuticals's revenue in 2024?

Apellis Pharmaceuticals's annual revenue for the twelve months ending Dec 31, 2024 was $781.37 million, a 97.02% increase year over year.

How much does Apellis Pharmaceuticals make in a day?

Based on Apellis Pharmaceuticals annual revenue for the past five years, APLS makes an average of $860,596.71 per day.

What was Apellis Pharmaceuticals's annual revenue growth in the past year?

As of Q4 2025, Apellis Pharmaceuticals's revenue has grown 42.11% year over year. This is 227.7 percentage points lower than the US Biotechnology industry revenue growth rate of 269.82%. Apellis Pharmaceuticals's revenue in the past year totaled $1.02 billion.

How much does Apellis Pharmaceuticals make in a year?

Apellis Pharmaceuticals's revenue by year for the past five years is:
  • Apellis Pharmaceuticals's revenue for the twelve months ending Dec 31, 2024 was $781.37 million, a 97.02% increase year over year.
  • Apellis Pharmaceuticals's annual revenue for Dec 31, 2023 was $396.59 million, a 425.83% increase from 2022.
  • Apellis Pharmaceuticals's annual revenue for 2022 was $75.42 million, a 13.31% increase from 2021.
  • Apellis Pharmaceuticals's annual revenue for 2021 was $66.56 million, a 73.44% decrease from 2020.
  • Apellis Pharmaceuticals's annual revenue for 2020 was $250.65 million, a Infinity% increase from 2019.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.